» Articles » PMID: 26134097

Expression of Interferon Lambda 4 Is Associated with Reduced Proliferation and Increased Cell Death in Human Hepatic Cells

Overview
Publisher Mary Ann Liebert
Date 2015 Jul 3
PMID 26134097
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Interferon lambda 4 (IFN-λ4) is a novel type-III interferon that can be generated only in individuals carrying a ΔG frame-shift allele of an exonic genetic variant (rs368234815-ΔG/TT). The rs368234815-ΔG allele is strongly associated with decreased clearance of hepatitis C virus (HCV) infection. Here, we further explored the biological function of IFN-λ4 expressed in human hepatic cells-a hepatoma cell line HepG2 and fresh primary human hepatocytes (PHHs). We performed live confocal imaging, cell death and proliferation assays, mRNA expression profiling, protein detection, and antibody blocking assays using transient and inducible stable in vitro systems. Not only did we observe significant intracellular retention of IFN-λ4 but also detected secreted IFN-λ4 in the culture media of expressing cells. Secreted IFN-λ4 induced strong activation of the interferon-stimulated genes (ISGs) in IFN-λ4-expressing and surrounding cells in transwell assays. Specifically, in PHHs, secreted IFN-λ4 induced expression of the CXCL10 transcript and a corresponding pro-inflammatory chemokine, IP-10. In IFN-λ4-expressing HepG2 cells, we also observed decreased proliferation and increased cell death. All IFN-λ4-induced phenotypes--activation of ISGs, decreased proliferation, and increased cell death--could be inhibited by an anti-IFN-λ4-specific antibody. Our study offers new insights into biology of IFN-λ4 and its possible role in HCV clearance.

Citing Articles

Structural studies of the IFNλ4 receptor complex using cryoEM enabled by protein engineering.

Grubbe W, Zhang B, Kauffman A, Bylehn F, Padol K, Jung H Nat Commun. 2025; 16(1):818.

PMID: 39827213 PMC: 11742915. DOI: 10.1038/s41467-025-56119-y.


Current Landscape of IFN-λ: Induction, Inhibition, and Potential Clinical Applications to Treat Respiratory Viral Infections.

Martinez-Espinoza I, Guerrero-Plata A Immunohorizons. 2023; 7(4):265-272.

PMID: 37071039 PMC: 10579847. DOI: 10.4049/immunohorizons.2200010.


Intracellular Accumulation of IFN-λ4 Induces ER Stress and Results in Anti-Cirrhotic but Pro-HCV Effects.

Onabajo O, Wang F, Lee M, Florez-Vargas O, Obajemu A, Tanikawa C Front Immunol. 2021; 12:692263.

PMID: 34497603 PMC: 8419317. DOI: 10.3389/fimmu.2021.692263.


Interferon lambda 4 impairs hepatitis C viral antigen presentation and attenuates T cell responses.

Chen Q, Coto-Llerena M, Suslov A, Teixeira R, Fofana I, Nuciforo S Nat Commun. 2021; 12(1):4882.

PMID: 34385466 PMC: 8360984. DOI: 10.1038/s41467-021-25218-x.


Double-edged effects of interferons on the regulation of cancer-immunity cycle.

Zhang X, Wang S, Zhu Y, Zhang M, Zhao Y, Yan Z Oncoimmunology. 2021; 10(1):1929005.

PMID: 34262796 PMC: 8253121. DOI: 10.1080/2162402X.2021.1929005.


References
1.
Terczynska-Dyla E, Bibert S, Duong F, Krol I, Jorgensen S, Collinet E . Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun. 2014; 5:5699. DOI: 10.1038/ncomms6699. View

2.
Fujino H, Imamura M, Nagaoki Y, Kawakami Y, Abe H, Hayes C . Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. J Gastroenterol. 2013; 49(12):1548-56. DOI: 10.1007/s00535-013-0924-9. View

3.
Lagging M, Romero A, Westin J, Norkrans G, Dhillon A, Pawlotsky J . IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology. 2006; 44(6):1617-25. DOI: 10.1002/hep.21407. View

4.
Key F, Peter B, Dennis M, Huerta-Sanchez E, Tang W, Prokunina-Olsson L . Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet. 2014; 10(10):e1004681. PMC: 4199494. DOI: 10.1371/journal.pgen.1004681. View

5.
Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H . Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 2003; 424(6948):516-23. DOI: 10.1038/nature01850. View